The following studies will be presented in the Press Program of the second European Multidisciplinary Conference in Thoracic Oncology, a multipartner initiative for physicians of all medical disciplines dealing with lung cancer and other thoracic malignancies.
The full text of the embargoed press releases/abstracts can be requested to the EMCTO Press Office at firstname.lastname@example.org. When the embargo lifts, the texts will be available in the ESMO Online Newsroom.
- Quick, easy test identifies aggressive type of lung cancer
in never-smokers (embargo: 25 February 2011, 8:00 CET)
Inexpensive and rapid test can effectively identify sub-group of never-smoking lung cancer patients whose tumors express molecule associated with increased risk of disease progression or recurrence.
Author: Ping Yang, US
- Oncogene AEG-1 strongly predicts response to erlotinib
treatment in EGFR-mutant lung cancer (embargo: 25 February
2011, 8:00 CET)
Researchers identified a gene whose expression level strongly predicts how well and how long certain lung cancer patients will respond to treatment with erlotinib.
Author: Rafael Rosell, Spain
- Bone drug zoledronic acid may help prevent spread of early
lung cancer (embargo: 25 February 2011, 8:00 CET)
Drug currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier state of treatment to prevent cancer from spreading.
Author: Michela Quirino, italy
- Radio-guided surgery, a safe and simple way to remove
potentially cancerous nodules in the lung (embargo: 26 February
2011, 8:00 CET)
Using tiny spheres of radioactive liquid to guide surgeons as they remove potentially cancerous material in the lungs is safe and more effective than other techniques.
Author: Luca Bertolaccini, Italy
- Phase III trial: erlotinib as effective as chemo, with fewer
side-effects, in patients whose disease progressed after first-line
treatment (embargo: 26 February 2011, 8:00 CET)
Targeted cancer drug erlotinib has comparable efficacy to chemotherapy and is better tolerated in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy.
Author: Tudor Ciuleanu, Romania